RTP Mobile Logo
Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia
Released March 2020

Proceedings from a CME symposium held during the 61st ASH Annual Meeting. Featuring perspectives from Drs Mark Levis, Daniel A Pollyea, Richard M Stone and Andrew H Wei. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).

    AML is the most common form of leukemia among adults, and in 2019 an estimated 21,450 cases were diagnosed and 10,920 individuals died from this disease. Untreated, AML is a uniformly fatal condition, and even with adequate therapy, the 5-year survival rate among all risk groups combined is approximately 22%. However, although much dismay has been expressed over the lack of progress in the management of this challenging disease, a number of recent scientific and therapeutic advances have begun to brighten the future for patients with AML. Of course, the rapid emergence of several newly approved treatment options and the unique toxicities and practical nuances associated with their use has added complexity to traditional therapeutic decision-making. These developments, as well as an array of ongoing attempts to find newer and better treatments for patients, require efforts to keep medical professionals informed.

    These video proceedings from a CME symposium held during the 2019 ASH Annual Meeting feature discussions with leading researchers with an expertise in AML regarding actual cases from their practices and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist with the formulation of up-to-date clinical management strategies.


    • Recognize the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to develop, adapt or refine current diagnostic testing algorithms for patients with AML.
    • Analyze how age, performance status and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with various presentations of AML.
    • Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
    • Develop an understanding of the mechanism of action of, available data with and current clinical role of available IDH1/2 inhibitors for patients with relapsed/refractory AML and an IDH1 or IDH2 mutation.
    • Evaluate the recent FDA approvals of novel agents targeting Bcl-2 and the hedgehog signaling pathway for patients with newly diagnosed AML ineligible for intensive therapy, and discern how these therapies can be optimally integrated into nonresearch care algorithms.
    • Design and implement a plan of care to prevent, recognize and manage side effects and toxicities associated with recently approved systemic therapies for AML to support quality of life and continuation of treatment.
    • Identify the mechanisms of action of and recall new data with investigational agents demonstrating promising activity in AML, and refer appropriate patients for participation in ongoing trials evaluating these approaches.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Mark Levis, MD, PhD
    Director, Adult Leukemia Program
    Co-Division Director, Hematologic Malignancies
    Professor of Oncology
    The Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Medicine
    Baltimore, Maryland

    Advisory Committee: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Menarini Group, Novartis; Contracted Research: Astellas, FUJIFILM Pharmaceuticals USA Inc, Novartis; Data and Safety Monitoring Board/Committee: Astex Pharmaceuticals.

    Daniel A Pollyea, MD, MS
    Associate Professor of Medicine
    Clinical Director of Leukemia Services
    Robert H Allen, MD Chair in Hematology Research
    Division of Hematology
    University of Colorado School of Medicine
    Aurora, Colorado

    Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, argenx, Celgene Corporation, Celyad, Forty Seven Inc, Gilead Sciences Inc, Janssen Biotech Inc, Pfizer Inc; Consulting Agreements: AbbVie Inc, Astellas, Daiichi Sankyo Inc, Genentech, Takeda Oncology; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: GlycoMimetics Inc, Tolero Pharmaceuticals.

    Richard M Stone, MD
    Director, Translational Research, Leukemia Division
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Amgen Inc, argenx, Arog Pharmaceuticals Inc, Astellas, BioLineRx, Celgene Corporation, Daiichi Sankyo Inc, Novartis, Pfizer Inc, Takeda Oncology, Trovagene; Data and Safety Monitoring Board/Committee: argenx, Celgene Corporation, Takeda Oncology.

    Andrew H Wei, MBBS, PhD
    Adjunct Associate Professor
    Department of Haematology
    Alfred Hospital
    Melbourne, Australia

    Advisory Committee: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Janssen Biotech Inc, MacroGenics Inc, Novartis, Pfizer Inc, Servier; Consulting Agreement: Servier; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Novartis, Servier; Speakers Bureau: AbbVie Inc, Novartis; Other: Royalty payments related to venetoclax research from Walter and Eliza Hall Institute of Medical Research.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by an educational grant from AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Celgene Corporation, Daiichi Sankyo Inc and Genentech, a member of the Roche Group.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: March 2020
    Expiration date: March 2021

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):


Evolving Paradigms in Up-Front Treatment for Older Patients or Those Ineligible for Intensive Chemotherapy

Assessment, Incidence and Clinical Significance of FLT3 Mutations in AML

Long-Term Treatment for Patients with AML with IDH Mutations

Other Novel Agents and Promising Strategies Under Evaluation for Patients with AML

Select Publications